RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

嵌合抗原受体 CD28 T细胞 免疫学 抗原 抗原提呈细胞 免疫系统 免疫疗法 CD19 癌症研究 生物 医学
作者
Sylvia Herter,Johannes Sam,Claudia Ferrara Koller,Sarah Diggelmann,Esther Bommer,Anne Schönle,Christina Claus,Marina Bacac,Christian Klein,Pablo Umaña
出处
期刊:Blood [American Society of Hematology]
卷期号:136 (Supplement 1): 40-40 被引量:5
标识
DOI:10.1182/blood-2020-134782
摘要

Synthetic T cell redirecting therapies, using chimeric antigen receptor (CAR)-T cells or CD3-bispecific antibodies targeting B-cell surface antigens such as CD19 and CD20, currently in clinical development, are emerging as promising, potential therapeutic approaches for the treatment of non-Hodgkin lymphomas (NHL). CD3-bispecific antibodies and first generation CAR-T cells only provide T cell receptor stimulation, so-called "signal 1", to the redirected T cells, but lack costimulatory, so-called "signal 2", support of those T cells. Agonism of costimulatory receptors on T cells, such as CD28 and/or 4-1BB, can increase the strength and durability of a T cell-mediated response via multiple mechanisms. Co-stimulation can enhance T cell specific cytotoxicity, proliferation, secretion of Th1-polarizing cytokines, recruitment of additional T cells via increased chemokine secretion, T cell metabolic fitness, and resistance to T-cell exhaustion and to activation-induced T-cell death. Indeed, 2nd generation CAR-T cells that incorporate CD28 or 4-1BB co-stimulation have replaced 1st generation ones in clinical development. However, complex manufacturing logistics and the need of specialized clinical centers for the administration of CAR-T cells significantly limit their broad application. In order to provide an off-the-shelf, synthetic T cell redirection approach delivering both signals 1 and 2 to T cells, CD3-bispecific antibodies would need combination with systemically administered T-cell costimulatory agonists. Yet, clinical development of 1st generation costimulatory agonists has not been successful to date due to on-target, off-tumor immune-mediated toxicity, such as hepatotoxicity. To overcome this limitation, we have generated a novel 4-1BB costimulatory agonist, CD19-targeted 4-1BBL (CD19-4-1BBL, RG6076, RO7227166), and are developing it in combination with a potent CD20xCD3 T cell bispecific antibody, CD20-TCB (RG6026 or glofitamab). CD19-4-1BBL consists of a trimeric, human 4-1BBL fused to a monovalent CD19-targeting IgG1 antibody with an engineered Fc region devoid of FcgR binding. As effective agonism of 4-1BB receptor requires crosslinking of more than three receptor units on a T cell, CD19-4-1BBL is systemically inactive unless it binds to CD19 and clusters on the surface of targeted B-cells to hyper-crosslink multiple 4-1BB receptors on redirected T cells. In our off-the-shelf, combination approach, glofitamab binds to CD20 on B-cells and engages CD3 on redirected T cells, providing signal 1 and inducing the expression of 4-1BB on those T cells. CD19-4-1BBL can then target those activated T cells and provide them with signal 2. In preclinical experiments, we show that CD19-4-1BBL can boost glofitamab-mediated cytokine release by activated T cells in healthy donor as well as DLBCL patient-derived PBMCs. Using a human diffuse large B cell lymphoma (DLBCL) tumor-bearing (WSU-DLCL2) fully humanized mouse model, we observed a CD19-4-1BBL dose-dependent, synergistic combination effect with glofitamab, leading to strongly increased T cell accumulation in tumors, tumor growth inhibition and regression. Importantly, CD19-4-1BBL was also able to prevent tumor escape to glofitamab monotherapy at late treatment time points in a fully humanized mouse model bearing large OCI-Ly18 human DLBCL tumors. Glofitamab monotherapy has recently demonstrated encouraging activity in relapsed/refractory NHL patients with reported complete response rates in DLBCL in the same range as those of 2nd generation CAR-T cells that already incorporate both T cell signals 1 and 2. The preclinical data we report here provide a strong rationale for adding CD19-4-1BBL-mediated T cell signal 2 to glofitamab in the clinic to further boost treatment efficacy and deliver an off-the-shelf, enhanced T cell redirection approach alternative to CAR-T cell therapy. CD19-4-1BBL is currently in clinical trials (NCT04077723). Disclosures Herter: Roche Glycart AG:Current Employment, Current equity holder in publicly-traded company, Patents & Royalties.Sam:Roche Glycart AG:Current Employment.Ferrara Koller:Roche Glycart AG:Current Employment.Diggelmann:Roche Glycart AG:Current Employment, Current equity holder in publicly-traded company.Bommer:Roche Glycart AG:Current Employment.Schönle:Roche Glycart AG:Current Employment.Claus:Roche Glycart AG:Current Employment.Bacac:Roche Glycart AG:Current Employment, Patents & Royalties.Klein:Roche:Current Employment, Current equity holder in publicly-traded company, Patents & Royalties.Umana:Roche Glycart AG:Current Employment, Current equity holder in publicly-traded company, Patents & Royalties.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
热切菩萨应助Jeffery426采纳,获得10
4秒前
10秒前
21秒前
Sofia完成签到 ,获得积分10
23秒前
刘天虎研通完成签到 ,获得积分10
26秒前
闪闪的荔枝完成签到 ,获得积分10
27秒前
zzz完成签到 ,获得积分10
28秒前
科研临床两手抓完成签到 ,获得积分10
35秒前
AJ完成签到 ,获得积分10
44秒前
娜娜子完成签到 ,获得积分10
45秒前
zijingsy完成签到 ,获得积分10
45秒前
坚强的广山给Enchanted的求助进行了留言
49秒前
机智柚子完成签到,获得积分10
49秒前
YCampion完成签到,获得积分10
50秒前
OCDer应助科研通管家采纳,获得200
52秒前
大个应助科研通管家采纳,获得10
52秒前
姬鲁宁完成签到 ,获得积分10
54秒前
kkkim完成签到 ,获得积分10
55秒前
虚心的正豪完成签到,获得积分10
1分钟前
1分钟前
yk完成签到 ,获得积分10
1分钟前
认真丹亦完成签到 ,获得积分10
1分钟前
现代元灵完成签到 ,获得积分10
1分钟前
忧伤的八宝粥完成签到,获得积分10
1分钟前
jun完成签到 ,获得积分10
1分钟前
yedo完成签到,获得积分10
1分钟前
www完成签到 ,获得积分10
1分钟前
1分钟前
真的耶完成签到 ,获得积分10
2分钟前
缓慢芙完成签到,获得积分10
2分钟前
xixialison应助hello采纳,获得10
2分钟前
留胡子的书桃完成签到 ,获得积分10
2分钟前
Xin完成签到 ,获得积分10
2分钟前
2分钟前
秋雪瑶应助温柔梦松采纳,获得10
2分钟前
cyskdsn发布了新的文献求助30
2分钟前
天璇完成签到,获得积分10
2分钟前
2分钟前
温柔梦松发布了新的文献求助10
2分钟前
打打应助科研通管家采纳,获得30
2分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2546210
求助须知:如何正确求助?哪些是违规求助? 2175672
关于积分的说明 5600310
捐赠科研通 1896399
什么是DOI,文献DOI怎么找? 946273
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557